[go: up one dir, main page]

GB1312760A - Method of contraception - Google Patents

Method of contraception

Info

Publication number
GB1312760A
GB1312760A GB2543472A GB2543470A GB1312760A GB 1312760 A GB1312760 A GB 1312760A GB 2543472 A GB2543472 A GB 2543472A GB 2543470 A GB2543470 A GB 2543470A GB 1312760 A GB1312760 A GB 1312760A
Authority
GB
United Kingdom
Prior art keywords
inhibiting action
dose
gestagen
april
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2543472A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to GB2543470D priority Critical patent/GB1279592A/en
Publication of GB1312760A publication Critical patent/GB1312760A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A41—WEARING APPAREL
    • A41C—CORSETS; BRASSIERES
    • A41C1/00—Corsets or girdles
    • A41C1/08—Abdominal supports
    • A41C1/10—Maternity corsets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Textile Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1312760 Contraceptive method SCHERING AG 24 April 1970 [24 April 1969] 25434/72. Divided out of 1311680 Heading A5B A method of contraception without suppression of ovulation comprises the administration of a dosage of a gestagen free from oestrogens during the period 3 hours before to 12 hours after coition. The gestagens used are those which are either, a) progestational hormones having no pituitary hypothalamic inhibiting action or, b) progestational hormones having pituitary hypothalamic inhibiting action but for which the minimum dose producing the required action is below the minimum threshold dose capable of producing any significant pituitary hypothalamic inhibiting action. The dose of gestagen is defined as the quantity of hormone having the gestagenic activity of 250Ág to 750Ág of d-norgestrel administered in the same way, the gestagenic activity considered being the peripheral activity measured by the effect on the cervical mucus.
GB2543472A 1969-04-24 1970-05-27 Method of contraception Expired GB1312760A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2543470D GB1279592A (en) 1970-05-27 1970-05-27 Improvements in or relating to wheel trims

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19691922005 DE1922005A1 (en) 1969-04-24 1969-04-24 Means and method of contraception

Publications (1)

Publication Number Publication Date
GB1312760A true GB1312760A (en) 1973-04-04

Family

ID=5732835

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1983670A Expired GB1311680A (en) 1969-04-24 1970-04-24 Contraceptive preparations and method of contraception
GB2543472A Expired GB1312760A (en) 1969-04-24 1970-05-27 Method of contraception

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB1983670A Expired GB1311680A (en) 1969-04-24 1970-04-24 Contraceptive preparations and method of contraception

Country Status (6)

Country Link
BE (1) BE749523A (en)
DE (1) DE1922005A1 (en)
FR (1) FR2042373B1 (en)
GB (2) GB1311680A (en)
IL (1) IL34345A (en)
NL (1) NL7005864A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5951480B2 (en) 2009-04-14 2016-07-13 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ On-demand contraceptive methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE716736A (en) * 1967-06-29 1968-12-18

Also Published As

Publication number Publication date
FR2042373A1 (en) 1971-02-12
BE749523A (en) 1970-10-26
FR2042373B1 (en) 1974-08-30
NL7005864A (en) 1970-10-27
DE1922005A1 (en) 1970-11-05
GB1311680A (en) 1973-03-28
IL34345A0 (en) 1970-06-17
IL34345A (en) 1974-01-14

Similar Documents

Publication Publication Date Title
GB1490099A (en) Contraceptive method and pack
US3755573A (en) Fertility control empoying quinestrol and quingestanol acetate
US4066757A (en) Oral contraceptive regimen
GB1433032A (en) Contraceptive method and preparations
Foss et al. Contraceptive action of continuous low doses of norgestrel
Blye The use of estrogens as postcoital contraceptive agents: Clinical effectiveness and potential mode of action
Klein et al. Gonadotropin, prolactin, and steroid hormone levels after discontinuation of oral contraceptives
CUNNINGHAM et al. The mechanism of ovulation inhibition by triamcinolone acetonide
Mishell Jr Effect of 6α-methyl-17α-hydroxyprogesterone on urinary excretion of luteinizing hormone
Greenblatt et al. Delay of menstruation with norethindrone, an orally given progestational compound
GB1253500A (en) Method of contraception
US4171358A (en) Novel contraceptive method
GB1312760A (en) Method of contraception
Mishell Jr et al. Effect of varying dosages of ethynodiol diacetate upon serum luteinizing hormone
GB2165750A (en) Contraceptive synergistic association
Shearman Excretion of ovarian steroids in patients treated with an “ovulation inhibitor”
GB1475790A (en) Contraceptive method and pack
Howie The progestogen-only pill
Rudel et al. Assay of the anti-oestrogenic effects of progestagens in women
Goldzieher Symposium on steroid hormones. 1. Synthetic progestational steroids. Their significance and use
Haspels Post-coital oestrogen in large doses
Swyer Progestogens and their clinical uses: Part I
Kistner Oral Contraceptives: Safety Factors in Prolonged Use of Progestin-Estrogen Combinations, Part 1
Hood et al. Enovid therapy for premenstrual tension
Brown-Grant The effects of some gonadal hormones on thyroid activity in the rabbit

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee